TY - JOUR
T1 - Omega-3 fatty acid monotherapy for pediatric bipolar disorder
T2 - A prospective open-label trial
AU - Wozniak, Janet
AU - Biederman, Joseph
AU - Mick, Eric
AU - Waxmonsky, James
AU - Hantsoo, Liisa
AU - Best, Catherine
AU - Cluette-Brown, Joanne E.
AU - Laposata, Michael
N1 - Funding Information:
This research was supported by a grant from the Stanley Foundation. Omega-3 fatty acid treatment was provided by Omegabrite®.
PY - 2007/5
Y1 - 2007/5
N2 - Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite® brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35% of these subjects had a response by the usual accepted criteria of > 50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.
AB - Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite® brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35% of these subjects had a response by the usual accepted criteria of > 50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.
UR - http://www.scopus.com/inward/record.url?scp=33947704134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947704134&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2006.11.006
DO - 10.1016/j.euroneuro.2006.11.006
M3 - Article
C2 - 17258897
AN - SCOPUS:33947704134
SN - 0924-977X
VL - 17
SP - 440
EP - 447
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 6-7
ER -
